about
Mycophenolate mofetil for relapsing-remitting multiple sclerosisMycophenolate mofetil for relapsing-remitting multiple sclerosisRole of immunosuppressive therapy for the treatment of multiple sclerosisCurrent and emerging therapies in multiple sclerosis: a systematic reviewDisease-modifying agents in multiple sclerosis.A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study.Mycophenolate mofetil and neurological diseases.Time dependent neuroprotection of mycophenolate mofetil: effects on temporal dynamics in glial proliferation, apoptosis, and scar formation.Basic immunosuppressive drugs outside solid organ transplantation.Improving outcomes in multiple sclerosis through early diagnosis and effective management.Immunosuppressive agents in multiple sclerosis.Treatment of multiple sclerosis in children and adolescents.Immunotherapy of multiple sclerosis: the state of the art.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis.Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.Medication Treatment in Multiple SclerosisZelldepletion und Myeloablation bei neuroimmunologischen Erkrankungen
P2860
Q24197935-8E4EF779-7A6B-4A9D-A2F9-05FD142916D6Q24200517-BC7EE33D-024E-4FF1-B271-A77AE2FD89A7Q26827467-6C469FA0-00CC-4BAB-BE0E-E608EE039549Q29010983-63EEC10E-89D4-4447-BD48-4B9068F064AAQ33670940-EC8CED52-2015-49F1-A089-0E0845985B87Q34409297-1C2669F1-3220-4546-8871-C76837BABD47Q34409308-E15F10F4-93EA-41A7-90B1-7CC9C4CF202DQ34713974-355DE3AB-CEF4-4A98-A512-C5E07DA84E6FQ36085865-8A94E9B9-B120-43EB-BAA1-26CFA25E01C9Q36198340-74A44B6D-1E2F-46EB-80D9-3EB86968744BQ36407314-5EB7E81A-762F-4513-B4FB-EA54483F9A1BQ36643255-DAC495F6-05AA-4ABA-B202-5BCF19ACA6BCQ36963189-BA3EF1DF-9150-45C5-987D-EA09F58F227AQ37693918-CD451E7C-BE32-4EF5-96BE-D1CAD6BF9BEBQ38083041-5B961459-5F77-4060-AEC8-703C01F9BAB2Q38101003-2252D50F-9AF2-4832-AB1A-BF54DA7A6F2EQ39032639-8F4E8774-6D8C-4DB6-8450-A5B2B6AC33BDQ40382676-3811FBB4-C540-49B7-913B-E096D0E737C6Q42608926-B43DCFB3-4593-4579-A41A-FCDCF4B222E1Q44718314-A5ED978D-613E-425D-BE99-6702CC6184B9Q45113442-9EC5A1A4-1619-4AB5-B0A4-8FC6A5590F66Q57083576-BC2BF58A-EA68-4F06-8E6C-9D574AD86FA1Q57912843-5A063D0A-2A2E-4E42-BE2C-C744D6F88394
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mycophenolate mofetil in multiple sclerosis.
@ast
Mycophenolate mofetil in multiple sclerosis.
@en
type
label
Mycophenolate mofetil in multiple sclerosis.
@ast
Mycophenolate mofetil in multiple sclerosis.
@en
prefLabel
Mycophenolate mofetil in multiple sclerosis.
@ast
Mycophenolate mofetil in multiple sclerosis.
@en
P2093
P1476
Mycophenolate mofetil in multiple sclerosis.
@en
P2093
Elliot M Frohman
Kathleen Hawker
Kristen Brannon
Michael K Racke
P356
10.1097/00002826-200403000-00006
P577
2004-03-01T00:00:00Z